Agile Therapeutics (NASDAQ:AGRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a report released on Monday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, Maxim Group reissued a hold rating on shares of Agile Therapeutics in a research note on Monday, March 18th.

Agile Therapeutics Price Performance

AGRX stock opened at $1.41 on Monday. The firm has a market cap of $9.67 million, a PE ratio of -0.39 and a beta of 1.58. Agile Therapeutics has a 12 month low of $0.20 and a 12 month high of $3.40. The firm has a 50 day simple moving average of $0.50 and a 200 day simple moving average of $0.88.

Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings data on Wednesday, May 15th. The specialty pharmaceutical company reported ($0.63) EPS for the quarter. The firm had revenue of $5.72 million during the quarter.

Hedge Funds Weigh In On Agile Therapeutics

A hedge fund recently raised its stake in Agile Therapeutics stock. Armistice Capital LLC lifted its holdings in Agile Therapeutics, Inc. (NASDAQ:AGRX) by 10.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 108,000 shares of the specialty pharmaceutical company’s stock after buying an additional 10,000 shares during the period. Armistice Capital LLC owned about 3.65% of Agile Therapeutics worth $211,000 as of its most recent SEC filing. 10.92% of the stock is owned by institutional investors.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.